Citations

Clear

415 citation(s) found for "Snyder, D".

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Abbott, Diana, Amorim, Ana , Houshyar, Samin , Adhikari, Arjab, Patel, Dilan A. , Wanjiku, Christopher, Bock, Allison M. , Any, Haya Al, Desai, Nidhi , Gupta, S. C. , Altomare, Nicole , Trotier, Daniel, Ricker, Edd , Hill, Brian T. , Gupta, Supriya , Major, Ajay , Abbott, Diana , Snyder, Jordan Andrew , Ahmed, Nausheen , Villasboas, José C. , Sharp, John, Voorhees, Timothy , Wallace, Danielle, Wagner, Charlotte B , Brooks, Taylor , Tsang, Mazie , Rajab, Mohamed , Iqbal, Madiha , Gupta, Supriya, Karmali, Reem , Pophali, Priyanka A. , Cherng, Hua‐Jay J. , Gupta, Arjun

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1798-1798

10.1182/blood-2025-1798 Get It

Abstract Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractory (R/R) follicular lymphoma (FL), but differ in treatment schedules and associated “time toxicity,” or contact days spent physically interacting with the healthcare system. While contact days can be estimated from clinical trials, real-world data provides a more nuanced depiction of treatment-related time burden, which may guide treatment decision-making. The comparative time toxicity of CAR-T vs BsAb in R/R FL is not defined. Methods We conducted a multicenter retrospective study of adults with R/R grade 1-3A FL who received standard-of-care CAR-T (axi-cel, tisa-cel, liso-cel) or BsAb (mosunetuzumab, epcoritamab) in the third-line or later setting before Jan 1, 2025. Time toxicity was defined as outpatient or inpatient days with physical health care system contact, counting multiple visits on the same day as only one day. All days after treatment initiation were counted, regardless of disease progression, therapy completion, or relation to FL therapy. Median contact days over 1-year time horizon were compared, stratified by CAR-T vs BsAb, prior lines of therapy (LOT, 2 vs 3+), and time intervals (0-1, 1-3, 3-6, 6-9, and 9-12 months). Progression-free survival (PFS) and overall survival (OS) were calculated from day of CAR-T infusion or day 1, cycle 1 for BsAb. Cox regression and propensity matching (by age, ECOG, refractory to prior LOT, POD24) were used to assess predictors and survival associations with contact days. Results Among 209 patients from 15 U.S. academic centers, median age was 64, 37% were female, 61% received CAR-T (80% axi-cel, 7% liso-cel, 13% tisa-cel) and 39% BsAb (93% mosun, 7% epcor). Most had Grade 1-2 FL (72%), advanced stage (84%), and extranodal disease (51%). Median prior LOT was 3 (range 2-15), 41% were refractory to prior LOT, and 52% had POD24. Median number of BsAb doses was 10 (range 1-36). Patients receiving BsAb were significantly older (p<.01) and had higher CIRS comorbidity scores (p<.02) in both 2 and 3+ prior LOT cohorts, and had higher ECOG scores (p=.01) and were less likely to be refractory to prior LOT (p=.029) in 3+ LOT cohort. There were no differences in POD24 rates between CAR-T and BsAb. Median PFS for the entire cohort was 3.6 yrs; median OS was not reached. In the 2 prior LOT cohort (N=75), 60% received CAR-T and 40% BsAb. With median follow-up of 1.5 years, median PFS was not reached for CAR-T and 1.6 yrs for BsAb (p<.0001). In the 3+ prior LOT cohort (N=134), 62% received CAR-T and 38% BsAb. With median follow-up of 2 yrs, median PFS was 3.6 yrs for CAR-T and 1.6 yrs for BsAb (p=.0044). In propensity matched analysis, PFS was shorter for BsAb in both 2 LOT (HR 9.0, 95% CI 1.14-71.04, p=.037) and 3+ LOT (HR 3.25, 95% CI 1.06-9.97, p=.039) cohorts as compared to CAR-T. There were no significant differences in OS between CAR-T and BsAb. Median contact days were significantly higher for CAR-T vs BsAb in the 0-1 month interval: 19 vs 8 days in 2 LOT (p<.0001) and 18 vs 7 days in 3+ LOT (p<.0001) cohorts. There were no differences in contact days between CAR-T vs BsAb in subsequent time intervals. Over 1 year, CAR-T had significantly more time toxicity than BsAb: median 51 vs 36 contact days in 2 LOT (p<.0001) and 64 vs 38 days in 3L+ LOT (p<.0001) cohorts; these remained significant in the matched analysis. B symptoms (p=.04) and Grade ≥3 cytopenias (p=.007) were associated with higher contact days in 3+ LOT cohort in univariable analysis. Higher contact days were associated with inferior PFS (HR 1.01, 95% CI 1.00-1.02, p=.032) and OS (HR 1.01, 95% CI 1.00-1.02, p=.038) in 3+ LOT cohort regardless of treatment type. Discussion In this large real-world cohort of patients with R/R FL, CAR-T therapy resulted in better PFS but more time toxicity over the first year as compared to BsAb therapy. Excess time toxicity from CAR-T was driven by more contact days in the first month of treatment. This study provides benchmark data for counseling patients about expected time burden of CAR-T (51-64 days) and BsAb (36-38 days) over the first year of these therapies. Further, with superior PFS of CAR-T in this study and minimal impact of time toxicity on survival outcomes, these data can be used to better support shared decision-making in R/R FL by addressing patient preferences regarding both contact days as well as duration of disease control.
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Cook, Eleanor , Rotz, Seth J. , Blacken, Robyn, Johnson, Darren, Alonso, Priscila Badia , French, Karis, Kent, Georgia , Huber, John , Hammoud, Miza Salim , Parker, Loretta , Kusnier, Katilyn , Lehmann, Leslie , Kapadia, Malika, Khera, Nandita , Nishitani, Miki , Craddock, John , Juckett, Mark, Maier, Steffani, O'Mathúna, Dónal, Phelan, Rachel , Young, Kylan, Jodele, Sonata , Snyder, Alana J. , Sampson, Megan , Dandoy, Christopher E. , Fitch, Taylor Jennelle , Badia, Priscila , Huber, John , Hammoud, Miza Salim , Myers, Kasiani , Craddock, John A , Jodele, Sonata , Schoettler, Michelle L , Sampson, Megan , Dandoy, Christopher E , Auletta, Jeffery J. , Bidgoli, Alan , French, Karis, Hartley, David , Maier, Steffani T. , O'Mathúna, Dónal, Nelson, Adam S. , Phelan, Rachel , Young, Kylan

Mayo Clinic

Pediatric Blood & Cancer | November 24, 2025 | Volume: 73 | Issue: 3 | Pages: No page available

10.1002/pbc.70001 | PMID 41277289 Get It

ABSTRACT Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
Landry, Alexander , Wang, Justin Z. , Patil, Vikas, Ajisebutu, Andrew, Gui, Chloe , Yefet, Leeor, Mamatjan, Yasin , Wei, Qingxia , Singh, Olivia, Mansouri, Sheila , Ehret, Felix , Capper, David , Cohen-Gadol, Aaron A, Behling, Felix , Sloan, Andrew E. , Chambless, Lola B. , Makarenko, Serge , Yip, Stephen , Tsang, Derek S. , Gao, Andrew , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Santarius, Thomas , Selman, Warren R., Couce, Marta , Wen, Patrick Y. , Walbert, Tobias , Felicella, Michelle M. , Brodie, Chaya , Snyder, James P., Saladino, Andrea , Schichor, Christian , Tonn, Jörg‐Christian, Goldbrunner, Roland , Timmer, Marco , Schimdt, Nils Ole, Jenkinson, Michael D. , Millward, Christopher P. , Islim, Abdurrahman I. , Fl, Behling, Santacroce, Antonio , Schittenhelm, Jens , Raleigh, David R. , Butowski, Nicholas , Westphal, Manfred , Lamszus, Katrin , Mawrin, Christian , Kurz, Sylvia C. , Zada, Gabriel , Yip, Stephen, Zherebitskiy, Viktor, Hnenny, Luke, Dunn, Ian F. , Moliterno, Jennifer , McDermott, Michael , Vogelbaum, Michael A. , Aldape, Kenneth, Alkividias, Tzannis, Short, Susan , Bos, Eelke M. , Dincer, Alper , Paßlack, Peter, Ehret, Felix, Lopez, Clara, Arvaniti, Christina , Benjamin, Carolina , Jackson, Christina , Jeyaretna, Sanjeeva, Scartoni, Daniele , Amelio, Dante , Ivanidze, Jana , Kien, Duong Trung, Millareschavez, Miguel, AlThgafi, Malak, LeRhun, Emilie, Smee, Robert, Muirhead, William , Molina, Eric Suero, Julius, Vitowanu, Chen, J., Mrugała, Maciej M. , Castro, Ana Valeria , Mamatjan, Yasin , Capper, David , Tatagiba, Marcos , Barnholtz-Sloan, Jill S , Yip, Stephen , Aldape, Kenneth , Zadeh, Gelareh , Short, Susan C , Yefet, Leeor S. , Ellenbogen, Yosef , Liu, Jeff , Singh, Olivia , Tabatabai, Ghazaleh , Tatagiba, Marcos , Barnholtz‐Sloan, Jill S. , Mansouri, Alireza , Brastianos, Priscilla K. , Shih, Helen A. , Bi, Wenya Linda , Huang, Raymond Y. , Wen, Patrick Yung , Lee, Ian , Malta, Tathiane Maistro , Castro, Ana Valéria , Noushmehr, Houtan , DiMeco, Francesco , Pollo, Bianca , Kaufmann, Timothy J. , Lachance, Daniel Honore , Giannini, Caterina , Galanis, Evanthia , Raghunathan, Aditya , Hanemann, C. Oliver , Au, Karolyn , Galldiks, Norbert , Herold‐Mende, Christel C. , Sahm, Felix , Jungk, Christine , Jungwirth, Gerhard , Deimling, Andreas von , Drummond, Katharine Jann , Morokoff, Andrew P. , Renovanz, Mirjam , Fougère, Christian la , Perry, Arie , Ricklefs, Franz , Horbinski, Craig , Ng, Ho‐Keung , Snuderl, Matija , Sulman, Erik P. , Cohen‐Gadol, Aaron , Javadpour, Mohsen , Fountain, Daniel Mark , Mathiesen, Tiit Illimar , Pathmanaban, Omar Nathan , Boutros, Paul C. , Fountas, Konstantinos N. , Walsh, Kyle M. , Carvalho, Bruno , Maas, Sybren L. N. , Deng, Maximilian Y. , Mehta, Minesh P. , Odia, Yazmín , Everson, Richard G. , Balogun, James , Calabrese, Evan , Karschnia, Philipp , Teske, Nico , Fariselli, Laura , Greve, Tobias , Ivan, Michael E , Palmer, Joshua D. , Ostrom, Quinn T. , Youngblood, Mark W. , Emerson, Sam, Weller, Michael , Martínez-Pérez, Rafael , Mukherjee, Raj, Cervio, Andrés , Turner, Clinton P. , Chen, Jiawei, Karmur, Brij S. , Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | November 15, 2025 | Volume: 28 | Issue: 2 | Pages: 430-439

10.1093/neuonc/noaf237 | PMID 41259653 Get It

Abstract Background DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed. Methods We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade. Results We first demonstrated that all risk groups benefit from gross total resection. All “high-risk, RT sensitive” tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (P = .003); after subtotal resection (STR), from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (P = .004). “Low-risk, RT sensitive cases” (n = 1207, 61.8%) also benefited from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, P = .03), suggesting that RT be considered in these patients. Neither “low-risk RT resistant” (n = 84, 4.3%) nor “high-risk RT resistant” (n = 356, 18.2%) cases benefited from RT, and the latter group was associated with universally poor outcomes. Conclusions We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.
A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia
Simha, Vinaya , LoPiccolo, Mary Kate , Platt, Anna , Brown, Rebecca J. , Johnson, Xandria, Carere, Deanna Alexis , Donnelly, Colleen , Snyder, Matthew T., Xing, Chao , Mathews, Thomas P. , Gopal, Purva , Tomchick, Diana R. , Agarwal, Anil , Garg, Abhimanyu , Brown, Rebecca J. , Ward, Stephen C. , DeBerardinis, Ralph J. , Xing, Chao

Mayo Clinic

Journal of Clinical Investigation | November 4, 2025 | Volume: 136 | Issue: 1 | Pages: No page available

10.1172/jci198888 | PMID 41186989 Get It

Integrating a motor domain enhances disease severity scales in an FTD‐ALS spectrum cohort
Snyder, Allison, Samra, Kiran , Wu, Tianxia, Russell, Lucy L. , Farren, Jennifer, Crook, Jody, Haselhuhn, Taryn, Porter, Katelyn, Szabo, Marcell , Duckett, Ariana, Lin, Fiona, Danielian, Laura E., Scholz, Sonja W. , Rosen, Howard J. , Rohrer, Jonathan D., Kwan, Justin , Scholz, Sonja W , Russell, Lucy L , Crook, Jody, Porter, Katelyn, Traynor, Bryan J. , Boeve, Bradley F. , Rohrer, Jonathan D.

Mayo Clinic

Alzheimer's & Dementia | October 29, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70786 | PMID 41152189 Get It

Abstract INTRODUCTION The Genetic Frontotemporal Initiative (GENFI) and Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)‐Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Longitudinal Frontotemporal Lobar Degeneration Study (ALLFTD) consortia developed Clinical Dementia Rating (CDR)‐derived scales with a motor domain to overcome systematic underestimation of disease severity by the CDR. We calculated disease severity scores using these scales in a mixed neurodegenerative cohort and correlated them with objective motor measures. METHODS The CDR plus National Alzheimer's Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD), CDR + NACC FTLD‐M (Motor), and Multidomain Impairment Rating (MIR) scores and motor measures were determined and correlated in 242 participants. RESULTS Both CDR + NACC FTLD‐M and MIR showed increased disease severity scores and correlated with motor measures. These findings were held in 81 amyotrophic lateral sclerosis (ALS) participants and correlated with the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. Including a motor domain required fewer study participants in a simulated clinical trial sample size calculation. DISCUSSION With a motor domain, CDR + NACC FTLD‐M and MIR improve disease severity classification and correlate with quantitative motor assessments. This addition more fully captures the extent of symptoms across the FTD‐ALS spectrum and improves clinical trial efficiency. Highlights CDR + NACC FTLD‐M and MIR strongly correlate with objective motor measures. The enhanced scales improve disease severity classification in FTD and ALS. Greater clinical trial efficiency is achieved using these enhanced scales.
Disparity in Timely Breast Cancer Treatment: Concordance with Commission on Cancer Quality Measures and the Influence of Socioeconomic Factors in the National Cancer Database
Nataliansyah, M. Muska , Xing, Yun , Boughey, Judy Caroline, Lizarraga, Ingrid M. , Xing, Yun, Boughey, Judy C. , Snyder, Rebecca A. , Mobley, Erin Michele

Mayo Clinic

Journal of the American College of Surgeons | October 16, 2025 | Volume: 242 | Issue: 1 | Pages: 79-89

10.1097/xcs.0000000000001649 | PMID 41100569 Get It

BACKGROUND: Significant disparities persist in timely, guideline-concordant breast cancer treatment across the US, impacting cancer outcomes. The influence of both patient-level and facility-level socioeconomic status (SES) on adherence to Commission on Cancer quality measures remains incompletely understood. STUDY DESIGN: We conducted a retrospective cohort study using the National Cancer Database to assess associations between patient and facility SES and concordance with timeliness of 3 Commission on Cancer breast cancer quality measures: surgery, multiagent chemotherapy, and radiotherapy, among patients diagnosed from 2018 to 2022. Multivariable logistic regression models were used to evaluate predictors of concordant care, including a composite measure of facility-level social risk. RESULTS: The analytic cohorts included 471,425 patients for surgery, 82,734 for chemotherapy, and 311,523 for radiotherapy. Black race, uninsured status, and lower educational attainment were each independently associated with lower odds of receiving guideline-concordant care across all measures. Patients treated at low-SES facilities had higher odds of receiving timely surgery (adjusted odds ratio [OR] 1.27, 95% CI 1.24 to 1.31) but lower odds of receiving timely chemotherapy (OR 0.85, 95% CI 0.79 to 0.91) and radiotherapy (OR 0.95, 95% CI 0.92 to 0.97) compared with those at other institutions. Facility type, fragmented care, and comorbidities also contributed to variation in concordance. CONCLUSIONS: Significant disparities in guideline-concordant breast cancer care persist by race, insurance, education, and facility-level social risk, highlighting intervention opportunities to improve outcomes for these already vulnerable populations. These findings highlight the importance of policy and institutional strategies that address both patient- and facility-level barriers to ensure equitable access to high-quality multidisciplinary treatment.
B-124 Evaluation of Anti-Citrullinated Peptide Antibody (ACPA) Result Normalization as Defined in the 2010 Rheumatoid Arthritis Classification Criteria Recommended by American College of Rheumatology/Alliance of Associations for Rheumatology (ACR/EULAR)
Ingvalson, Justen, Trautschold, Daniel, Vanderboom, Patrick M. , Snyder, Melissa, Wu, Jack, Snyder, Melissa

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.521 Get It

Abstract Background Anti-citrullinated peptide antibodies (ACPA) (tested as anti-cyclic citrullinated peptide [CCP] antibodies) are frequently ordered in the evaluation of patients with suspected rheumatoid arthritis (RA) and considered to be specific biomarkers for RA. The 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for RA include both ACPA and rheumatoid factor in their scoring system, despite limited standardization of commercially available anti-CCP antibody tests. In an attempt to overcome this limitation, the classification criteria recommends using multiples of the assay-specific upper limit of normal (ULN) to normalize results and standardize classification. This study evaluates the correlation between normalized results from different assays and the concordance in result classification according to the ACR/EULAR criteria. Methods A total of 265 samples with ACPA ordered as part of routine clinical care were tested on four commercial anti-CCP antibody assays, including QUANTA Lite CCP3 IgG ELISA (Werfen) (Negative: <20 Units), QUANTA Flash CCP3 chemiluminescence immunoassay (Werfen) (Negative: <20 Chemiluminescent Units), EUROIMMUN Anti-CCP ELISA (IgG) (EUROIMMUN) (Negative: <=5 Relative Units/mL), and Elecsys anti-CCP electrochemiluminescence immunoassay (Roche) (Negative: <17.0 Units/mL). The QUANTA Lite and EUROIMMUN ELISA were performed on the Agility platform (Dynex), QUANTA Flash was performed on BioFlash platform (Werfen), and Elecsys anti-CCP was performed on Cobas e601 platform (Roche). All testing was performed according to manufacturer’s instructions. Results from each assay were converted to the multiples of assay-specific ULN as the normalized results. Regression analysis was performed, and the coefficient of determination (R²) was calculated to assess the correlation between paired assays. The concordance in result classification across assays was also investigated using both assay specific cut-offs and the ACR/EULAR criteria-defined cut-offs: Negative (<=1xULN), Low positive (>1xULN and <3xULN), High positive (>=3xULN). Results Using assay-specific cut-offs, 63 samples were negative on all assays. 202 samples were positive on at least one assay, of which 79 (39%) were positive across all assays. The overall concordance of qualitative result was 54% ([63+79]/265). After result normalization using multiples of assay-specific ULNs, the highest correlation was observed between the EUROIMMUN ELISA and Elecsys anti-CCP (R²=0.83), despite differences in methodology and manufacturer. The lowest correlation was observed between QUANTA Lite and QUANTA Flash (R²=0.49), even though both are from the same manufacturer although methodologies differ. When applying the criteria-defined cut-offs, 64 samples were negative on all assays. 130 samples were classified as low positive on at least one assay; however, only 3 (2%) samples were classified as low positive across all assays. 103 samples were classified as high positive on at least one assay, of which 54 (52%) were classified as high positive across all assays. With result normalization, the overall concordance in result classification across all assays using the criteria-defined cut-offs were 46% ([64+3+54]/265). Conclusion Despite normalization using multiplies of assay-specific ULN values, the inter-assay correlation remains suboptimal, and the concordance in result classification is limited. These findings suggest that the anti-CCP antibody results from different assays may not be interchangeable even after normalization as recommended by current criteria, potentially impacting disease classification.
B-112 HLA-DQ Genotypes as Predictors of Serological Positivity for Celiac Disease in Pediatric Patients
Liu, Danting , Vanderboom, Patrick M. , Snyder, Melissa R.

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.509 Get It

Abstract Background Celiac disease (CeD) is a chronic autoimmune disorder that can affect people of any age. Both ingestion of gluten and the presence of human leukocyte antigens (HLA)-DQ2 or DQ8 are required for disease development. In adults, correlation between HLA-DQ2/DQ8 allele combinations and tissue transglutaminase (tTG) antibody positivity has been well described. In comparison, this association in pediatric patients is less defined. In this study, we evaluated the roles of HLA-DQ2 and HLA-DQ8 as predictors of tTG-IgA positivity in a pediatric cohort, aiming to enhance understanding of CeD risk assessment in this diagnostic group. Methods Retrospective data were collected from individuals who underwent CeD diagnostic testing at Mayo Clinic Laboratories between 2011 and 2024; all patients were tested for total IgA, HLA-DQ typing, and tTG-IgA. Total IgA was measured using quantitative nephelometry on the BN™ II System (Siemens); HLA-DQ typing was performed using reverse sequence-specific oligonucleotide (SSO) DNA typing (LABType SSO kits, One Lambda, Thermo). tTG-IgA was tested using an enzyme-linked immunosorbent assay (QUANTA Lite® h-tTG IgA, Werfen Diagnostics). Those with total IgA below the age-specific reference interval were excluded from this analysis. Logistic regression was used to evaluate the association between HLA-DQ haplotypes and tTG-IgA positivity to assess the risk gradient across different HLA-DQ genotypes in children. Results The cohort identified in this study consisted of 115,499 individuals for whom total IgA, HLA-DQ typing and tTG-IgA testing was performed. Within this cohort, 20,676 (17.9%) were pediatric patients (age<=18 at the time of testing). Pediatric patients tested for CeD exhibited a slightly higher prevalence of at least one copy of HLA-DQ2 or DQ8 compared to adults (57.6% vs 55.4%, p<0.001). Additionally, these patients showed significantly higher rates of tTG-IgA positive across all genotypes, particularly those carrying HLA-DQ2.5 or DQ8, with positivity rates 1.2 to 2.3 times higher than in adults (p<=0.01). However, in non-permissive genotypes, the positivity rates were 0.3% (p=0.95), for both populations, indicating comparable specificity. Individuals with homozygous HLA-DQ2.5/DQ2.5 and HLA-DQ2.5/DQ2.2 showed the highest risks for tTG-IgA positivity with ORs of 85.7 (95% CI: 55.1-137.7) and 78.5 (95% CI: 51.3-124.3), respectively. Moderate risk was observed for HLA-DQ2.5/DQ8 with an OR of 49.0 (95% CI: 32.1-77.3), followed by single copy HLA-DQ2.5 (OR=35.0, 95% CI: 24.0-53.4) and homozygous HLA-DQ8/DQ8 (OR=21.7, 95% CI: 11.7-39.4). Although single copies of HLA-DQ2.2 and HLA-DQ8 showed lower risks with ORs of 5.4 and 8.9 (95% CI: 3.2-9.2 and 5.7–13.9), their combination increased the OR to 22.6 (95% CI: 13.0-39.2), similar to homozygous HLA-DQ8. Conclusion This large cohort study demonstrates the predictive value of HLA-DQ genotypes for pediatric CeD seropositivity. Notably, pediatric patients showed slightly higher prevalence and positivity rates compared to adults, particularly among those with homozygous HLA-DQ2.5/DQ2.5 and HLA-DQ2.5/DQ2.2 genotypes, which exhibited the highest risks for tTG-IgA positivity. The findings confirm that HLA-DQ2.5 is the main driver of serology positivity and suggest that HLA-DQ8 also influences serological positivity in pediatric patients, which can enhance targeted screening and potentially inform decisions regarding the necessity of duodenal biopsy.
International, Multispecialty Expert Consensus on Nomenclature for Facial Paralysis
Oyer, Samuel L. , Baptista, Rachel, Boahene, Kofi , Byrne, Patrick J., Chuang, David Chwei‐Chin , Dey, Jacob K. , Diels, Jackie , Hadlock, Tessa A. , Hetzler, Laura , Klebuc, Michael, Labbé, D., Loyo, Myriam , Miller, Matthew Q. , Pepper, Jon‐Paul , Rozen, Shai M. , Snyder‐Warwick, Alison K. , Stephan, Scott J., Tzafetta, Kallirroi , Azizzadeh, Babak , Byrne, Patrick , Dey, Jacob K , Lassaletta, Luis , Loyo, Myriam , Miller, Matthew Q , Pepper, Jon-Paul , Rozen, Shai , Azizzadeh, Babak , Borschel, Gregory Howard , Guerreschi, Pierre , Gur, Eyal , Kim, Jennifer , Mardini, Samir

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | September 30, 2025 | Volume: 27 | Issue: 5 | Pages: 408-415

10.1177/26893614251363957 | PMID 40876002 Get It

Background: Variable terminology is used in the literature to describe facial synkinesis and hypertonicity following incomplete recovery from facial paralysis and its associated medical and surgical treatments. Study Objectives: Establish a nomenclature consensus for this condition among a group of facial nerve experts. Design Type: Consensus study. Methods: Using modified Delphi methodology, an international, multidisciplinary group of facial nerve experts reviewed the terminology for the name of the clinical condition and treatments of interest. Online surveys and a virtual discussion were performed to establish consensus, defined a priori as agreement by 80% of the group. Results: Twenty-five facial nerve experts established consensus after three Delphi rounds. Consensus terminology for the condition is “facial synkinesis” with 84% agreement. Medical treatment is termed “chemodenervation” with 100% agreement. Surgical treatments including “selective facial neurectomy,” “selective facial neurotomy,” “selective facial myectomy,” and “selective facial myotomy,” were defined and reached agreement of 100%. Conclusions: This international group of facial nerve experts has recommended standardized nomenclature for the condition of facial synkinesis and its various treatments. While “facial synkinesis” reached consensus as the preferred term, some experts noted it may insufficiently describe the full clinical spectrum, which includes muscle hypertonicity, weakness, and spontaneous twitching.
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Janelidze, Shorena, Bali, Divya , Dolado, Anna Orduña , Binette, Alexa Pichet , Rahmouni, Nesrine , Blennow, Kaj, Doré, Vincent , Feizpour, Azadeh , Rowe, Christopher C., Villeneuve, Sylvia , Petersen, Ronald C., Jack, Clifford R. , Groups, ADNI, ALFA, and PREVENT-AD Study, Adegoke, Olusegun, Hussen, Kedir Adem, Aisen, Paul, Ajayi, Adeyinka, Amaza, Hannatu, Apostolova, Liana G. , Ashford, Miriam T. , Ayo, Omobolanle, Bernard, Marie , Bernhardt, Haley, Boatwright, Virginia, Borowski, Bret, Brylska, Magdalena, Buckholtz, Neil, Cabrera, Yuliana, Cairns, Nigel J. , Carrillo, Maria, Choe, Mark, Clanton, Taylor, Conti, Cat, Craft, Hannah, Crawford, Karen , DeCarli, Charles , Benedetto, Joseph Di, Diaz, Adam , Drake, Erin, Faber, Kelley, Felmlee, Joel P. , Fidell, Andrea, Flenniken, Derek , Fockler, Juliet , Forghanian-Arani, Arvin, Frank, R.T., Franklin, Erin , Glittenberg, Matt, Gunter, Jeff, Guzmán, Vanessa , Harvey, Danielle, Hedberg, Caitie, Hergesheimer, Lindsey, Hoang, Isabella, Jackson, Jonathan , Jagust, William, Jahanshad, Neda , Jenkins, Cecily, Jiménez, Gustavo , Jin, Chengshi , Kachaturian, Zaven, Kaddurah-Daouk, Rima, Kantarci, Kejal, Karlawish, Jason , Khachaturian, Zaven S., Knaack, Alexander , Korecka, Magdalena , Kormos, Adrienne, Germano, Kaori Kubo, Kwang, Winnie, Lacy, Kaci, Landau, Susan, Lopresti, Brian J. , Magana, Fabiola, Mahboubi, Payam, Malone, Ian G., Masliah, Eliezer , Masterman, Donna, Matoush, Leonard, Miller, Melanie J. , Molchan, Susan, Montine, Tom, Moore-Weiss, John, Neu, Scott, Nosheny, Rachel L. , Ogwang, Sheila, Okonkwo, Ozioma, Parkins, Shaniya, Perrin, Richard J. , Petersen, Ronald, Pizzola, Jeremy, Potter, Zoë, Potter, William Z., Rafii, Michael, Raman, Rema , Reyes, Calvin, Reyes, Denise , Robison, Justin , Chen, Stephanie Rossi, Ryan, Laurie, Sachdev, Pallavi, Saito, Naomi , Salazar, Jennifer, Thao, Mai Seng, Shaffer, Elizabeth , Shaw, Leslie M. , Silverberg, Nina, Strong, Joe, Talavera, Sandra , Taylor‐Reinwald, Lisa, Thal, Leon J., Thomas, Lisa , Thompson, Paul , Tosun, Duygu , Trojanowki, John Q., Sacrey, Diana Truran, Villemagne, Victor L. , Walter, Sarah , Wan, Yang , Ward, Chad, Webb, Caitlin, Weiner, Michael W. , Weisensel, Trinity, Zimmerman, Caileigh, Poirier, Judes, Breitner, John C.S. , Badawy, Mohamed , Baril, Andrée‐Ann, Aguilar, Ricardo A, Gorriti, Annabella B, Gispert, Lidia C, Martinez, Alba C, Iglesias, Ruth D, Julian, Sherezade F, Serra, P, González‐Escalante, Armand , Penas, Laura H, Rodriguez, Gema H, Ninou, Jordi H, Gamaz, Laura Iglesias, Knezevic, Iva, Alvarez, Paula M, Diaz, Tania M, Palacios, Eva , Ballester, A, Mendez, Sandra P, Freixedes, Laura Ros, Vila, Aleix S, Harster, Lluis S, Prat, Anna S, Jaramillo, Marc V, Jack, Clifford R , Feizpour, Azadeh , Doré, Vincent , Pichet Binette, Alexa , Salvadó, Gemma , Janelidze, Shorena , Therriault, Joseph , Brum, Wagner Scheeren , Stomrud, Erik , Mattsson, Niklas , Palmqvist, Sebastian , Coomans, Emma M. , Teunissen, Charlotte E. , Flier, Wiesje M. van der , Benzinger, Tammie L.S. , Gispert, Juan Domingo , Blennow, Kaj , Alcolea, Daniel , Fortea, Juan , Johnson, Sterling C. , Rosa-Neto, Pedro , Schindler, Suzanne E. , Suárez‐Calvet, Marc , Ossenkoppele, Rik , Hansson, Oskar , Groups, ADNI, ALFA, and PREVENT-AD Study, Aisen, Paul , Barnes, Lisa L. , Beckett, Laurel , Das, Sandhitsu R. , Donohue, Michael , Drake, Erin, Erickson, Claire M. , Fletcher, Evan M. , Arani, Arvin , Foroud, Tatiana , Fox, Nick C. , Frank, Richard, González, Hector, Green, Robert C. , Grill, Joshua D. , Harkins, Kristin , Ho, Carole , Hsiao, John , Jo, Taeho, Kaddurah‐Daouk, Rima , Kantarci, Kejal , Koeppe, Robert A. , Largent, Emily A. , Lee, Edward B. , Lee, Virginia M.‐Y. , Morris, John C. , Nho, Kwangsik T. , Nir, Talia M. , Nudelman, Kelly , Okonkwo, Ozioma, Petersen, Ronald, Rabinovici, Gil D. , Rafii, Michael S. , Reid, Robert, Reyes, Denise, Risacher, Shannon L. , Mindt, Mónica Rivera , Sachdev, Pallavi, Saykin, Andrew J. , Schwarz, Christopher G. , Senjem, Matthew L. , Li, Shen , Smith, Stephanie R. , Snyder, Peter J. , Thomopoulos, Sophia I. , Toga, Arthur W. , Vemuri, Prashanthi , Yushkevich, Paul A. , Badawy, Mohamed, Baillet, Sylvain , Minguillón, Carolina , Brugulat‐Serrat, Anna , Cacciaglia, Raffaele , Campo, Marta del , Pascual, Maria, Rodríguez‐Fernández, Blanca , Vilor‐Tejedor, Natàlia

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1122

10.1001/jamaneurol.2025.3217 | PMID 40952756 Get It

Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures Aβ status, determined by CSF or Aβ PET biomarkers. Results Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and Relevance The findings highlight the potential of plasma p-tau217 as a stand-alone test—or when used in a sequential 2-step approach alongside PET or CSF testing—as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments.